- SEK4.05bn
- SEK3.82bn
- -SEK414.00m
Brief: Linc Q3 Net Asset Value Down At SEK 2,807 Million
Brief: Linc: Alder Therapeutics Secures SEK 20 Million Of Financing
Brief: Linc's Gesynta Pharma Reports Results From An Exploratory Clinical Study Of The Drug Candidate GS-248
Brief: Linc, Its Unit Production Sweden And Lantmännen Sell Swevet
Brief: Linc NAV At End-March At SEK 3,228 Mln, Corresponding To SEK 55.7 Per Share
Brief: Linc Net Q4 Profit SEK Down At 17.2 Mln
Brief: Linc Invests In Oncorena's Phase I/II Study Of Orellanine
Brief: Linc Q3 EBIT Down At SEK 101.4 Mln
Brief: Linc: Exercise Of The Over-Allotment Option In The IPO
Brief: Offering Price For Linc's IPO Set At SEK 67 Per Share